Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CAMB in Fluconazole-Resistant VVC
NCT03167957Phase 2Withdrawn
- Sponsor
- Matinas BioPharma
- Start
- Dec 2019
- Primary completion
- Dec 2020
- Modality
- Lipid-based Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of MAT2203 in vulvovaginal candidiasis (VVC) (2 arms), sponsored by Matinas BioPharma. Primary endpoints: Proportion of subjects with clinical cure at 28 days and Proportion of subjects with mycological eradication at 28 days. Planned start Dec 2019; status: withdrawn.
02
Drugs
MAT2203
03
Conditions
vulvovaginal candidiasis (VVC)
Beyond the preview
Go deeper on NCT03167957.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03167957.